InvestLog
LRMR Larimar Therapeutics, Inc. logo

LRMR Larimar Therapeutics, Inc.

Healthcare
$3.45-3.36%ClosedMarket Cap: $295.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.86

P/S

0.00

EV/EBITDA

-0.71

DCF Value

$1.06

FCF Yield

-44.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-134.1%

ROA

-79.6%

ROIC

-106.6%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-29.6M$—
Q4 null$0.00$-62.5M$—
FY null$0.00$-165.7M$—
Q3 null$0.00$-47.7M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$12.00

Target (Median)

$12.00

Target Range

$12.00 - $12.00

1 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell
WedbushOutperform
2026-05-18
WedbushOutperform
2026-03-20
CitigroupBuy
2026-02-25
OppenheimerOutperform
2025-10-02
WedbushOutperform
2025-09-30

Trading Activity

Insider Trades

View All
Truitt Josephdirector
SellWed May 20
THOMAS FRANK Edirector
SellWed May 20
SHERMAN JEFFREY Wdirector
SellWed May 20
LEFF JONATHAN Sdirector
SellWed May 20
Hamilton Thomas Edwarddirector
SellWed May 20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.91

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Peers

ACIU logoACIUALT logoALTAMRN logoAMRNANNX logoANNXANRO logoANRODBVT logoDBVTENGN logoENGNKRRO logoKRROKYTX logoKYTXLXEO logoLXEO